Aktis Oncology (AKTS) surged 50% intraday on Friday following its Nasdaq debut, driven by strong investor interest in its upsized initial public offering. The clinical-stage biotech priced 17.7 million shares at $18 each, raising $318 million, with Eli Lilly committing to a $100 million investment.
The company’s focus on targeted radiopharmaceuticals for solid tumors and its $1 billion valuation post-IPO fueled optimism. Key pipeline assets include Ac-AKY-1189 (Phase 1b for Nectin-4 cancers) and Ac-AKY-2519 (IND planned for 2026), alongside strategic isotope partnerships and a forthcoming cGMP facility.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments